![Atossa Therapeutics, Inc. logo](/logos/ATOS.webp)
Atossa Therapeutics, Inc.
NASDAQ:ATOS
Overview | Financials
Company Name | Atossa Therapeutics, Inc. |
Symbol | ATOS |
Currency | USD |
Price | 1.33 |
Market Cap | 167,256,810 |
Dividend Yield | 0% |
52-week-range | 0.62 - 2.31 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Website | https://www.atossatherapeutics.com |
An error occurred while fetching data.
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD